Pharmacokinetic profile of novel reduced-dose Danziten™ (nilotinib tablets) versus Tasigna® (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis

20250 citationsJournal Articlehybrid Open Access

Authors

Michael J. Mauro

Jerald P. Radich · Seattle University

Paras Jain · IBC Pharmaceuticals (India)

David J. Sequeira · Alexion Pharmaceuticals (United States)

Francesco Bellanti · Certara (United States)

Dan Douer · University of Southern California

Abstract

Nilotinib tablets 142 and 190 mg provide bioequivalent exposures to 300 mg and 400 mg capsules under fasted conditions and substantially smaller effects of food on exposure.

Topics & Keywords

Chronic Myeloid Leukemia Treatments HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Cancer Chemotherapy and Pharmacology

Volume 95, Issue 1, pp. 56-56

DOI: 10.1007/s00280-025-04777-6

Field-Weighted Citation Impact: 0.00